[Spirapril in patients with hypertension: clinical experience in Germany].
OBJECTIVE
To examine efficacy and tolerability of a single daily dose of 6 mg quadropril (spirapril).


METHODS
An open multicenter study enrolled 5000 out-door patients with hypertension. All the patients received an ACE inhibitor quadropril for 3 months with four control visits (on week 0, 4, 8 and 12).


RESULTS
Quadropril caused a marked decrease in systolic and diastolic blood pressure. At the end of the study 89.4% of patients had a systolic blood pressure reduction of at least 15 mm Hg and 85.4% had a diastolic blood pressure reduction of at least 10 mm Hg. There were no clinically significant heart rate changes. The overall tolerability of the drug was estimated as good or very good in 95.3% of patients. Only 2.9% of patients had side effects during treatment with once daily dose of 6 mg quadropril. No serious side effects were observed.


CONCLUSIONS
6 mg daily dose of quadropril is an effective and safe therapy for arterial hypertension.
Schmidt
J
J
Kraul
H
H
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004656:Enalapril; C052555:spirapril
Primenenie spiraprila u patsientov s arterial'noĭ gipertonieĭ - klinicheskiĭ opyt v Germanii.